EGFR (Epidermal Growth Factor Receptor) inhibitors

Name
EGFR (Epidermal Growth Factor Receptor) inhibitors
Accession Number
DBCAT005725
Description

Not Available

ATC Classification
Drugs
DrugDrug Description
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
Drugs & Drug Targets
DrugTargetType
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
PanitumumabEpidermal growth factor receptortarget
NecitumumabEpidermal growth factor receptortarget